Immatics NV
NASDAQ:IMTX

Watchlist Manager
Immatics NV Logo
Immatics NV
NASDAQ:IMTX
Watchlist
Price: 7.58 USD Market Closed
Market Cap: 904.7m USD
Have any thoughts about
Immatics NV?
Write Note

Intrinsic Value

IMTX's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one IMTX stock under the Base Case scenario is 4.76 USD. Compared to the current market price of 7.58 USD, Immatics NV is Overvalued by 37%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

IMTX Intrinsic Value
4.76 USD
Overvaluation 37%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Immatics NV

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for IMTX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about IMTX?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Immatics NV

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Immatics NV

Provide an overview of the primary business activities
of Immatics NV.

What unique competitive advantages
does Immatics NV hold over its rivals?

What risks and challenges
does Immatics NV face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Immatics NV.

Provide P/S
for Immatics NV.

Provide P/E
for Immatics NV.

Provide P/OCF
for Immatics NV.

Provide P/FCFE
for Immatics NV.

Provide P/B
for Immatics NV.

Provide EV/S
for Immatics NV.

Provide EV/GP
for Immatics NV.

Provide EV/EBITDA
for Immatics NV.

Provide EV/EBIT
for Immatics NV.

Provide EV/OCF
for Immatics NV.

Provide EV/FCFF
for Immatics NV.

Provide EV/IC
for Immatics NV.

Show me price targets
for Immatics NV made by professional analysts.

What are the Revenue projections
for Immatics NV?

How accurate were the past Revenue estimates
for Immatics NV?

What are the Net Income projections
for Immatics NV?

How accurate were the past Net Income estimates
for Immatics NV?

What are the EPS projections
for Immatics NV?

How accurate were the past EPS estimates
for Immatics NV?

What are the EBIT projections
for Immatics NV?

How accurate were the past EBIT estimates
for Immatics NV?

Compare the revenue forecasts
for Immatics NV with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Immatics NV and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Immatics NV against its competitors.

Analyze the profit margins
(gross, operating, and net) of Immatics NV compared to its peers.

Compare the P/E ratios
of Immatics NV against its peers.

Discuss the investment returns and shareholder value creation
comparing Immatics NV with its peers.

Analyze the financial leverage
of Immatics NV compared to its main competitors.

Show all profitability ratios
for Immatics NV.

Provide ROE
for Immatics NV.

Provide ROA
for Immatics NV.

Provide ROIC
for Immatics NV.

Provide ROCE
for Immatics NV.

Provide Gross Margin
for Immatics NV.

Provide Operating Margin
for Immatics NV.

Provide Net Margin
for Immatics NV.

Provide FCF Margin
for Immatics NV.

Show all solvency ratios
for Immatics NV.

Provide D/E Ratio
for Immatics NV.

Provide D/A Ratio
for Immatics NV.

Provide Interest Coverage Ratio
for Immatics NV.

Provide Altman Z-Score Ratio
for Immatics NV.

Provide Quick Ratio
for Immatics NV.

Provide Current Ratio
for Immatics NV.

Provide Cash Ratio
for Immatics NV.

What is the historical Revenue growth
over the last 5 years for Immatics NV?

What is the historical Net Income growth
over the last 5 years for Immatics NV?

What is the current Free Cash Flow
of Immatics NV?

Discuss the annual earnings per share (EPS)
trend over the past five years for Immatics NV.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Immatics NV

Current Assets 512.8m
Cash & Short-Term Investments 490.5m
Receivables 3.9m
Other Current Assets 18.4m
Non-Current Assets 64.5m
PP&E 61.8m
Intangibles 1.5m
Other Non-Current Assets 1.2m
Current Liabilities 128.9m
Accounts Payable 22.1m
Accrued Liabilities 2.8m
Other Current Liabilities 104.1m
Non-Current Liabilities 65.8m
Long-Term Debt 13.2m
Other Non-Current Liabilities 52.6m
Efficiency

Earnings Waterfall
Immatics NV

Revenue
115.5m EUR
Operating Expenses
-182.7m EUR
Operating Income
-67.2m EUR
Other Expenses
11.4m EUR
Net Income
-55.8m EUR

Free Cash Flow Analysis
Immatics NV

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

IMTX Profitability Score
Profitability Due Diligence

Immatics NV's profitability score is 30/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
ROE is Increasing
ROIC is Increasing
Exceptional 1-Year Revenue Growth
30/100
Profitability
Score

Immatics NV's profitability score is 30/100. The higher the profitability score, the more profitable the company is.

IMTX Solvency Score
Solvency Due Diligence

Immatics NV's solvency score is 62/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Short-Term Solvency
Low D/E
Long-Term Solvency
62/100
Solvency
Score

Immatics NV's solvency score is 62/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

IMTX Price Targets Summary
Immatics NV

Wall Street analysts forecast IMTX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for IMTX is 18.19 USD with a low forecast of 15.15 USD and a high forecast of 21 USD.

Lowest
Price Target
15.15 USD
100% Upside
Average
Price Target
18.19 USD
140% Upside
Highest
Price Target
21 USD
177% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for IMTX?

Click here to dive deeper.

Dividends

Immatics NV
does not pay dividends
Shareholder Yield

Current shareholder yield for IMTX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

IMTX News

Profile

Immatics NV Logo
Immatics NV

Country

Germany

Industry

Biotechnology

Market Cap

904.7m USD

Dividend Yield

0%

Description

Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 188 full-time employees. The firm is focused on the discovery and development of T-Cell eceptors with the goal of enabling a robust and specific T-Cell response against these targets. The firm develops targeted immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER). Its wholly owned pipeline comprises of eight therapeutic programs, of which four are in clinical trials, including IMA201 (MAGEA4/8), IMA202 (MAGEA1) and ACTolog IMA 101 (Multi-target pilot trial) for solid cancers and IMA203 (PRAME) for hematological and solid cancers, as well as four are in preclinical development, including IMA204 (COL6A3) and IMA401 (Cancer testis antigen) for solid cancers, and ACTallo IMA301 (Cancer testis antigen) and IMA402 (Cancer testis antigen) for hematological and solid cancers.

Contact

BADEN-WUERTTEMBERG
Tuebingen
Paul Ehrlich-Strasse 15
+4970715397700.0
immatics.com

IPO

-

Employees

188

Officers

CEO, MD, Member of Management Board & Executive Director
Dr. Harpreet Singh Ph.D.
Co-Founder & Chief Innovation Officer
Dr. Toni Weinschenk Ph.D.
Chief Financial Officer
Mr. Arnd Christ MBA
Chief Operations Officer
Mr. Steffen Walter Ph.D.
General Counsel & Secretary
Mr. Edward A. Sturchio
Chief Development Officer
Dr. Carsten Reinhardt M.D., Ph.D.
Show More
Chief Medical Officer
Mr. Cedrik M. Britten M.D.
Head of Strategy
Mr. Jordan Silverstein
Co-Founder & Member of the Scientific Advisory Board
Dr. Hans-Georg Rammensee Ph.D.
Vice President of SEC Reporting & Accounting
Mr. Ephraim Hofsäß M.Sc.
Show Less

See Also

Discover More
What is the Intrinsic Value of one IMTX stock?

The intrinsic value of one IMTX stock under the Base Case scenario is 4.76 USD.

Is IMTX stock undervalued or overvalued?

Compared to the current market price of 7.58 USD, Immatics NV is Overvalued by 37%.

Back to Top